Amylin reportedly turns down Bristol's $3.5B acquisition bid

03/28/2012 | Bloomberg

Bristol-Myers Squibb offered to purchase Amylin Pharmaceuticals for $3.5 billion, sources said, but Amylin rejected the unsolicited bid. Analysts said Amylin, which makes diabetes medicines Byetta and Bydureon, might attract a bigger transaction from AstraZeneca or another company looking to augment its pipeline.

View Full Article in:

Bloomberg

Published in Brief: